Cancer Statistics, 2000

Robert T. Greenlee, MPH, Taylor Murray, Sherry Bolden, Phyllis A. Wingo, PhD, MS

Abstract

The Surveillance Research Program of the American Cancer Society's Department of Epidemiology and Surveillance Research reports its annual compilation of estimated cancer incidence, mortality, and survival data for the United States in the year 2000. After 70 years of increases, the recorded number of total cancer deaths among men in the US declined for the first time from 1996 to 1997. This decrease in overall male mortality is the result of recent downturns in lung and bronchus cancer deaths, prostate cancer deaths, and colon and rectum cancer deaths.

Despite decreasing numbers of deaths from female breast cancer and colon and rectum cancer, mortality associated with lung and bronchus cancer among women continues to increase. Lung cancer is expected to account for 25% of all female cancer deaths in 2000.

This report also includes a summary of global cancer mortality rates using data from the World Health Organization. (CA Cancer J Clin 2000;50:7-33.)

Mr. Greenlee is an Epidemiologist with the Surveillance Research Program, Department of Epidemiology and Surveillance, American Cancer Society, Atlanta, GA.

Mr. Murray is Manager, Surveillance Data Systems, with the Surveillance Research Program, Department of Epidemiology and Surveillance, American Cancer Society, Atlanta, GA.

Ms. Bolden is Manager, Surveillance Information Services, with the Surveillance Research Program, Department of Epidemiology and Surveillance, American Cancer Society, Atlanta, GA.

Dr. Wingo is Director of the Surveillance Research Program, Department of Epidemiology and Surveillance, American Cancer Society, Atlanta, GA. The authors thank Cheryll Cardinez, Marlo Corrao, April Harris, Elyse Luke, and Kate O'Brien for their assistance in preparation of this manuscript.

This article is also available online at http://www.ca-journal.org.

Introduction

Cancer is an important public health concern in the United States and around the world. To provide an up-to-date perspective on the occurrence of cancer, the American Cancer Society presents an overview of cancer frequency, incidence, mortality, and survival statistics for the year 2000.

Methods

ESTIMATED NEW CANCER CASES

Because the US does not have a nationwide cancer registry, the exact number of new cases of cancer diagnosed each year in the US and in individual states is not known. Consequently, we first estimated the number of new cancer cases occurring annually in the US from 1979 through 1996 using population data reported by the US Bureau of the Census and age-specific cancer incidence rates collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. We fitted these annual cancer case estimates to an autoregressive quadratic model to forecast the number of cancer cases expected to be diagnosed in the US in the year 2000 (Table 1, Fig. 1).²

Between 1987 and 1992, the incidence rate of prostate cancer increased 85%, followed by a decline of 29% between 1992 and 1996.³ The sharp increase in incidence followed by the decline in recent years probably reflects extensive use of prostate-specific antigen (PSA) screening in a previously unscreened population and the subsequent increase in diagnoses at an early stage.⁴ We assumed that the number of prostate cancer cases would approximate the rates observed prior to widespread use of PSA screening, and there-

fore, we estimated new cases of prostate cancer for 2000 using a linear projection based on data from 1979 to 1989.

Because cancer incidence rates and case counts for 1979 through 1996 were not available for many states, we could not use the methods mentioned above to estimate new cases for individual states (Table 3). To derive these estimates, we assumed that the ratio of cancer deaths to cancer cases for each state was the same as the ratio for the US.²

ESTIMATED CANCER DEATHS

We estimated the number of cancer deaths expected to occur in the US in the year 2000 using underlying cause-of-death data from death certificates as reported to the National Center for Health Statistics (Table 2, Fig. 2).⁵ The recorded numbers of cancer deaths occurring annually from 1979 to 1997 were fitted to an autoregressive quadratic model to forecast the number of cancer deaths expected to occur in the US in 2000. The estimated number of cancer deaths for each state was calculated with the same modeling procedure used for the total US (Table 4).²

OTHER STATISTICS

Mortality statistics for the leading causes of death (Tables 6, 7, and 12), the leading causes of death from cancer (Tables 8, 9), and cancer mortality rates from 1930 to 1996 (Figs. 5, 6) were obtained using data from the National Center for Health Statistics.⁵ Incidence rates (Table 10, Figs. 3, 4), the probability of developing cancer (Table 5), and five-year relative survival rates (Tables 11, 13; Figs. 7, 8) were obtained from the SEER program.^{3,6} We computed global cancer mortality rates (Table 14) using data compiled by the World Health Organization.7 We included data from countries that have: 1) submitted data for at least one of the years between 1994 and 1997 using codes from the ninth or tenth revision of the International Classification of Diseases; 2) populations of 500,000 or more; 3) death

registration of at least 82%; and 4) a proportion of deaths with medically certified cause of death of at least 95%.⁸

Selected Findings

EXPECTED NUMBERS OF NEW CANCER CASES

In the year 2000, we estimate that about 1,220,100 new cases of invasive cancer will be diagnosed in the US (Table 1). This estimate does not include carcinoma in situ of any site except urinary bladder, and it does not include basal and squamous cell cancers of the skin. Approximately 1.3 million cases of basal and squamous cell skin cancers, 42,600 cases of breast carcinoma in situ, and 28,600 cases of in situ melanoma are expected to be newly diagnosed in 2000.

Among men, the most common cancers in 2000 are expected to be cancers of the prostate, lung and bronchus, and colon and rectum (Fig. 1). The prostate is the leading site for cancer incidence, accounting for 29% of new cancer cases in men. This year, 180,400 new cases of prostate cancer are expected to be diagnosed.

Among women, the three most commonly diagnosed cancers are expected to be cancers of the breast, lung and bronchus, and colon and rectum (Fig. 1). Cancers occurring at these sites are expected to account for over 50% of new cancer cases in women. Breast cancer alone is expected to account for 182,800 new cancer cases (30%) in 2000.

TRENDS IN CANCER INCIDENCE

For all sites combined, SEER cancer incidence rates appeared to peak in 1992 and decreased an average of -2.2% per year from 1992 to 1996. Similar declines have been seen recently for specific leading cancer sites (Figs. 3 and 4).

Breast cancer incidence rates have remained approximately level during the 1990s; however, they appear to be decreasing in younger women. Decreases in colon and rectum cancer incidence rates began in the mid-1980s, and have been observed among both males and females in all racial/ethnic groups (with the exception of American Indian women in whom data were not sufficient to make a determination as to the direction of this trend). Incidence rates of colon and rectum cancer declined significantly between 1990 and 1996, on average -2.1% per year. 9

A downturn in the incidence of lung and bronchus cancer in males began in the late 1980s, and between 1990 and 1996, incidence rates decreased significantly, -2.6% per year. Incidence rates of lung and bronchus cancer among females are stabilizing, and have begun to decline among women aged 40 to 59.9 Prostate cancer incidence rates also declined significantly between 1990 and 1996, on average -2.0% per year.

EXPECTED NUMBERS OF CANCER DEATHS In 2000, an estimated 552,200 Americans are expected to die of cancer—more than 1,500 people a day (Table 2). Most cancer deaths in men (52%) in the year 2000 are expected to be from cancers of the lung and bronchus, prostate, and colon and rectum (Fig. 2).

Among women, cancers of the lung and bronchus, breast, and colon and rectum are expected to account for more than half of all cancer deaths in 2000 (Fig. 2). In 1987, lung cancer surpassed breast cancer as the leading cause of cancer death in women and is expected to account for 25% of all female cancer deaths in 2000.

TRENDS IN THE RECORDED NUMBER OF CANCER DEATHS

Following more than 70 years of increases, the recorded number of total cancer deaths among men in the US has declined for the first time, from a peak of 281,898 in 1996 to 281,110 in 1997. This promising change results from recent downturns in each of the top three causes of cancer death among men. Lung and bronchus cancer deaths among men declined from a peak of 92,493 in 1993 to 91,278 in 1997.

Prostate cancer deaths declined from a peak of 34,902 in 1994 to 32,891 in 1997. Colon and rectum cancer deaths among men were highest in 1990 at 28,635 and have declined to 28,075 in 1997.

Among women, the recorded number of total cancer deaths continues to increase, although the rate of increase has diminished in recent years. The upward trend among females is primarily due to sustained increases in the number of deaths from lung and bronchus cancer. The numbers of deaths from breast and colorectal cancers among females, however, have begun to decline. Breast cancer deaths were highest in 1995 at 43,844 and have declined to 41,943 in 1997. Colorectal cancer deaths among women have declined from a recent peak of 29,237 in 1995 to 28,621 in 1997, although these deaths reached their all-time high in 1984 at 29,522.

TRENDS IN CANCER DEATH RATES

Death rates for all cancers combined peaked in 1991 and decreased an average -0.7% per year from 1991 to 1996 (Figs. 5 and 6). Significant decreases have been seen among both males and females, persons younger than 65 years of age, and among whites, blacks, and Hispanics.

Breast cancer death rates in females decreased an average of -1.8% per year between 1990 and 1996; decreases were more pronounced among white women and among younger women. During the period from 1990 to 1996, colon and rectum cancer death rates decreased significantly, on average -1.7% per year.

Similar to trends in incidence, significant decreases in death rates for lung and bronchus cancer have occurred only among males (on average -1.6% per year between 1990 and 1996); rates among females recently have begun to slow and appear to be stabilizing. Prostate cancer death rates decreased on average -1.6% per year during the period between 1990 and 1996.

TRENDS IN CANCER BY RACE/ETHNICITY

Overall rates of cancer incidence vary considerably among racial and ethnic groups (Table 10). Blacks have the highest cancer incidence rates: They are about 60% more likely to develop cancer than are Hispanics and Asian/Pacific Islanders and more than twice as likely to develop cancer as American Indians. Between 1990 and 1996, incidence rates decreased among whites (-1.2% per year), Hispanics (-1.7% per year), and American Indians (-0.7% per year), and remained relatively stable among blacks and Asian/Pacific Islanders.³

White women are more likely to develop breast cancer than are women of other racial and ethnic groups, and black women are more likely to develop cancers of the colon and rectum.³ Black men have the highest incidence rates for cancers of the colon and rectum, lung and bronchus, and prostate. They are also at least 50% more likely to develop prostate cancer than men of other racial and ethnic groups.

Blacks are about 33% more likely to die of cancer than are whites, and more than twice as likely to die of cancer as are Asian/Pacific Islanders, American Indians, and Hispanics. Between 1990 and 1996, mortality rates decreased significantly among whites (-0.5% per year), blacks (-0.9% per year), and Hispanics (-0.6% per year); remained relatively stable among Asian/Pacific Islanders; and may be increasing among American Indians.³

Black women are more likely to die of breast (see article by Dignam in this issue of *CA*, page 50) and colon and rectum cancers than are women of any other racial or ethnic group, and they have approximately the same lung and bronchus cancer death rate as white women. As was seen with incidence rates, black men have the highest mortality rates of colon and rectum, lung and bronchus, and prostate cancers.³

CANCER IN CHILDREN

Cancer is the second leading cause of death among children between one and 14 years of age in the US; accidents are the most frequent cause of death in this age group (Table 12). The most commonly occurring cancers in children are leukemias (in particular, acute lymphocytic leukemia), tumors of the central and sympathetic nervous systems, lymphomas, soft-tissue sarcomas, and renal tumors.3 Over the past 20 years, there have been significant improvements in the five-year relative survival rate for many childhood cancers, especially acute lymphocytic and acute myeloid leukemia, non-Hodgkin's lymphoma, and Wilms' Tumor (Table 13). Between 1974/1976 and 1989/1995, fiveyear relative survival rates for childhood cancers at all sites combined improved from 56% to 75%.

Limitations and Future Challenges

Our estimates of the expected numbers of new cancer cases and cancer deaths should be interpreted with caution when tracking trends over time. These estimates may vary considerably from year to year, particularly for rare cancers and for states with smaller populations. We therefore discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. The recorded number of cancer deaths and cancer death rates from the National Center for Health Statistics, and SEER cancer incidence rates are generally more informative statistics for the purpose of tracking cancer trends. For example, breast cancer incidence rates increased about 1% per year between 1979 and 1982, increased 4% per year between 1982 and 1987, and were approximately constant between 1987 and 1996. Despite the stabilization of incidence rates during the latter time period, the estimates of new breast cancer cases increased between 1988 and 1996.

Our estimates are based on the most currently available cancer mortality and

incidence data; however, these data are three and four years old, respectively, at the time that the estimates are calculated. As such, the effects of large changes occurring in the three- or four-year interval between 1996 or 1997 and 2000 cannot be captured by our modeling efforts. Finally, our estimates of new cancer cases are based on incidence rates for the geographic locations that participate in the SEER program and, therefore, may not be representative of the total US.

Despite these limitations, our estimates do describe current patterns of cancer incidence and mortality in the US. Such estimates will assist our continuing efforts to reduce the public health burden of cancer as we enter the 21st century.

References

- National Cancer Institute: SEER Cancer Incidence Public-Use Database, 1973-1996, August 1998 Submission. US Department of Health and Human Services, Public Health Service. Bethesda, MD, 1999.
- 2. Wingo PA, Landis S, Parker S, et al: Using can-

- cer registry and vital statistics data to estimate the number of new cancer cases and deaths in the United States for the upcoming year. J Reg Management 1998;25:43-51.
- 3. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK (eds). SEER Cancer Statistics Review, 1973-1996. National Cancer Institute, Bethesda, MD, 1997.
- 4. Wingo PA, Landis S, Ries LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997;47:239-242.
- National Center for Health Statistics, Division of Vital Statistics. Multiple Cause-of-Death for ICD9, 1996 Data Public-Use Documentation. (Web site) www.cdc.gov/nchswww/about/major/dvs/mcd/1996 mcd.htm 1999.
- DEVCAN: Probability of Developing or Dying of Cancer (Software), version 4. Feuer EJ, Wun LM. National Cancer Institute, Bethesda, MD, 1999.
- 7. World Health Organization: WHO Mortality Database. (Web site) www.who/int/whosis/mort 1999.
- 8. World Health Organization: World Health Statistics Annual, 1996. Geneva, Switzerland, 1997.
- Wingo PA, Ries LAG, Giovino GA, et al. Annual report to the nation on the status of cancer 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999;91: 675-690.

ANNOUNCING...

Continuing Medical Education in CA—A Cancer Journal for Clinicians

The American Cancer Society is pleased to announce that a Continuing Medical Education activity will be included in each upcoming issue of *CA—A Cancer Journal for Clinicians*.

When? Starting March/April 2000!

What? AMA PRA category 1 CME credits or AAFP Elective hours. Topics to include management of cancer pain; malignant melanoma; new treatments for smoking cessation; lymphedema; and mind-body integration.

How? Save each issue of *CA*. Review the article designated for CME credit. Complete the accompanying CME quiz and program evaluation. Submit by fax or mail for CME credit, according to instructions.

Who? The American Cancer Society, Inc., is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

| | | T | able 1 | | | |
|-----------|-----|--------|--------|----|---------|-----------|
| Estimated | New | Cancer | Cases | by | Gender, | US, 2000* |

| | Total | Male | Female |
|-----------------------------------|------------------|-----------------|----------------|
| All Sites | 1,220,100 | 619,700 | 600,400 |
| Oral cavity & pharynx | 30,200 | 20,200 | 10,000 |
| Tongue | 6,900 | 4,500 | 2,400 |
| Mouth | 10,900 | 6,500 | 4,400 |
| Pharynx | 8,200 | 5,900 | 2,300 |
| Other oral cavity | 4,200 | 3,300 | 900 |
| Digestive system | 226,600 | 117,600 | 109,000 |
| Esophagus Stomach | 12,300 21,500 | 9,200 13,400 | 3,100 |
| Small intestine | 4,700 | 2,300 | 8,100 2,400 |
| Colon | 93,800 | 43,400 | 50,400 |
| Rectum | 36,400 | 20,200 | 16,200 |
| Anus, anal canal, & anorectum | 3,400 | 1,400 | 2,000 |
| Liver & intrahepatic bile duct | 15,300 | 10,000 | 5,300 |
| Gallbladder & other biliary | 6,900 | 2,900 | 4,000 |
| Pancreas | 28,300 | 13,700 | 14,600 |
| Other digestive organs | 4.000 | 1,100 | 2,900 |
| Respiratory system | 179,400 | 101,500 | 77,900 |
| Larynx | 10,100 | 8,100 | 2,000 |
| Lung & bronchus | 164,100 | 89,500 | 74,600 |
| Other respiratory organs | 5,200 | 3,900 | 1,300 |
| Bones & joints | 2,500 | 1,500 | 1,000 |
| Soft tissue (including heart) | 8,100 | 4,300 | 3,800 |
| Skin (excluding basal & squamous) | 56,900 | 34,100 | 22,800 |
| Melanomas-skin | 47,700 | 27,300 | 20,400 |
| Other non-epithelial skin | 9,200 | 6,800 | 2,400 |
| Breast | 184,200 | 1,400 | 182,800 |
| Genital system | 265,900 | 188,400 | 77,500 |
| Uterine cervix | 12,800 | | 12,800 |
| Uterine corpus | 36,100 | | 36,100 |
| Ovary | 23,100 | | 23,100 |
| Vulva | 3,400 | | 3,400 |
| Vagina & other genital, female | 2,100 | 100 100 | 2,100 |
| Prostate Testis | 180,400 | 180,400 | |
| Penis & other genital, male | 6,900 1,100 | 6,900 1,100 | |
| Urinary system | 86,700 | 58,600 | 28,100 |
| Urinary bladder | 53,200 | 38,300 | 14,900 |
| Kidney & renal pelvis | 31,200 | 18,800 | 12,400 |
| Ureter & other urinary organs | 2,300 | 1,500 | 800 |
| Eye & orbit | 2,200 | 1,200 | 1,000 |
| Brain & other nervous system | 16,500 | 9,500 | 7,000 |
| Endocrine system | 20,200 | 5,600 | 14,600 |
| Thyroid | 18,400 | 4,700 | 13,700 |
| Other endocrine | 1,800 | 900 | 900 |
| Lymphoma | 62,300 | 35,900 | 26,400 |
| Hodgkin's disease | 7,400 | 4,200 | 3,200 |
| Non-Hodgkin's lymphoma | 54,900 | 31,700 | 23,200 |
| Multiple myeloma | 13,600 | 7,300 | 6,300 |
| Leukemia | 30,800 | 16,900 | 13,900 |
| Acute lymphocytic leukemia | 3,200 | 1,800 | 1,400 |
| Chronic lymphocytic leukemia | 8,100 | 4,600 | 3,500 |
| Acute myeloid leukemia | 9,700 | 4,800 | 4,900 |
| Chronic myeloid leukemia | 4,400 | 2,600 | 1,800 |
| Other leukemia | 5,400 | 3,100 | 2,300 |
| Other & unspecified primary sites | 34,000 | 15,700 | 18,300 |

^{*}Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

| | | Table 2 | | | |
|-----------|--------|-----------|---------|-----|-------|
| Estimated | Cancer | Deaths by | Gender, | US, | 2000* |

| | Total | Male | Female |
|-----------------------------------|---------|---------|------------------|
| All Sites | 552,200 | 284,100 | 268,100 |
| Oral cavity & pharynx | 7,800 | 5,100 | 2,700 |
| Tongue | 1,700 | 1,100 | 600 |
| Mouth | 2,300 | 1,300 | 1,000 |
| Pharynx | 2,100 | 1,500 | 600 |
| Other oral cavity | 1,700 | 1,200 | 500 |
| Digestive system | 129,800 | 69,300 | 60.500 |
| Esophagus | 12,100 | 9,200 | 2,900 |
| Stomach | 13,000 | 7,600 | 5,400 |
| Small intestine | 1,200 | 600 | 600 |
| Colon | 47,700 | 23,100 | 24.600 |
| Rectum | 8,600 | 4,700 | 3,900 |
| Anus, anal canal, & anorectum | 500 | 200 | 300 |
| Liver & intrahepatic bile duct | 13,800 | 8,500 | 5,300 |
| Gallbladder & other biliary | 3,400 | 1,200 | 2,200 |
| Pancreas | 28,200 | 13,700 | 14,500 |
| Other digestive organs | 1,300 | 500 | 800 |
| Respiratory system | 161,900 | 93,100 | 68,800 |
| Larvnx | 3,900 | 3,100 | 800 |
| Lung & bronchus | 156,900 | 89,300 | 67,600 |
| Other respiratory organs | 1,100 | 700 | 400 |
| Bones & joints | 1,400 | 800 | 600 |
| Soft tissue (including heart) | 4,600 | 2,200 | 2,400 |
| Skin (excluding basal & squamous) | 9,600 | 6,000 | 3,600 |
| Melanomas-skin | 7.700 | 4,800 | 2.900 |
| Other non-epithelial skin | 1.900 | 1,200 | 700 |
| Breast | 41,200 | 400 | |
| | | | 40,800 26,500 |
| Genital system | 59,000 | 32,500 | |
| Uterine cervix | 4,600 | | 4,600 |
| Uterine corpus | 6,500 | | 6,500 |
| Ovary | 14,000 | | 14,000 |
| Vulva | 800 | | 800 |
| Vagina & other genital, female | 600 | 24.222 | 600 |
| Prostate | 31,900 | 31,900 | |
| Testis | 300 | 300 | |
| Penis & other genital, male | 300 | 300 | 72.72.2 |
| Urinary system | 24,600 | 15,700 | 8,900 |
| Urinary bladder | 12,200 | 8,100 | 4,100 |
| Kidney & renal pelvis | 11,900 | 7,300 | 4,600 |
| Ureter & other urinary organs | 500 | 300 | 200 |
| Eye & orbit | 200 | 100 | 100 |
| Brain & other nervous system | 13,000 | 7,100 | 5,900 |
| Endocrine system | 2,100 | 1,000 | 1,100 |
| Thyroid | 1,200 | 500 | 700 |
| Other endocrine | 900 | 500 | 400 |
| Lymphoma | 27,500 | 14,400 | 13,100 |
| Hodgkin's disease | 1,400 | 700 | 700 |
| Non-Hodgkin's lymphoma | 26,100 | 13,700 | 12,400 |
| Multiple myeloma | 11,200 | 5,800 | 5,400 |
| Leukemia | 21,700 | 12,100 | 9,600 |
| Acute lymphocytic leukemia | 1,300 | 700 | 600 |
| Chronic lymphocytic leukemia | 4,800 | 2,800 | 2,000 |
| Acute myeloid leukemia | 7,100 | 3,900 | 3,200 |
| Chronic myeloid leukemia | 2,300 | 1,300 | 1,000 |
| Other leukemia | 6,200 | 3,400 | 2,800 |
| Other & unspecified primary sites | 36,600 | 18,500 | 18,100 |
| | | 10.000 | 10.100 |

Table 3 Estimated New Cancer Cases by Site and State, US, 2000*

| State | All Sites | Female Breast | Uterine Cervix | Colon & Rectum | Uterine Corpus | Lung & Bronchus | Melanoma | Non- Hodgkin's Lymphoma | Kidney | Prostate | Urinary Bladder |
|----------------|--------------|------------------|-------------------|-------------------|-------------------|--------------------|----------|-------------------------------|--------|----------|--------------------|
| Alabama | 21,500 | 2,700 | 200 | 1,800 | 500 | 3,000 | 900 | 900 | 400 | 3,500 | 800 |
| Alaska | 1,500 | 200 | | 200 | | 200 | 100 | 100 | | 100 | 100 |
| Arizona | 20,300 | 2.800 | 200 | 2.000 | 600 | 2.800 | 1.000 | 900 | 500 | 3,300 | 900 |
| Arkansas | 13,700 | 1,900 | 100 | 1,300 | 400 | 2,200 | 400 | 500 | 400 | 2,200 | 500 |
| California | 113,200 | 17,900 | 1,300 | 11,400 | 3,200 | 14,000 | 5,000 | 5,300 | 2,900 | 16,400 | 5,200 |
| Colorado | 13,400 | 2,000 | 100 | 1,400 | 400 | 1,500 | 700 | 700 | 400 | 1,800 | 600 |
| Connecticut | 15,400 | 2,300 | 100 | 1,500 | 500 | 1,900 | 600 | 700 | 400 | 2,300 | 800 |
| Delaware | 3,900 | 500 | 100 | 400 | 100 | 600 | 100 | 200 | 100 | 600 | 200 |
| Dist. of Col. | 2,700 | 500 | - | 300 | 100 | 300 | - | 100 | - | 600 | 100 |
| Florida | 88,100 | 12,000 | 900 | 9,100 | 2,500 | 12,600 | 3,500 | 4,000 | 2,000 | 13,700 | 4,300 |
| Georgia | 29,400 | 4,600 | 400 | 2,800 | 900 | 4,200 | 1,000 | 1,000 | 700 | 4,400 | 1,000 |
| Hawaii | 4,300 | 500 | _ | 400 | 100 | 500 | 100 | 200 | 100 | 700 | 100 |
| Idaho | 4,700 | 700 | _ | 500 | 100 | 600 | 200 | 200 | 200 | 800 | 200 |
| Illinois | 55,100 | 8,900 | 600 | 6,000 | 1,600 | 7,300 | 1,900 | 2,500 | 1,400 | 7,800 | 2,400 |
| Indiana | 27,900 | 4,200 | 300 | 3,100 | 800 | 4,000 | 1,000 | 1,200 | 800 | 3,900 | 1,200 |
| lowa | 14,200 | 2,100 | 100 | 1,900 | 600 | 1,900 | 500 | 700 | 400 | 2,200 | 600 |
| Kansas | 11,900 | 1,600 | 100 | 1,200 | 300 | 1,600 | 500 | 500 | 300 | 1,800 | 500 |
| Kentucky | 20,500 | 2,700 | 300 | 2,200 | 500 | 3,400 | 900 | 800 | 600 | 2,600 | 600 |
| Louisiana | 20,800 | 3,200 | 300 | 2,200 | 500 | 2,900 | 700 | 800 | 600 | 3,200 | 700 |
| Maine | 6,800 | 900 | 100 | 700 | 100 | 1,000 | 200 | 300 | 200 | 900 | 400 |
| Maryland | 22,600 | 3,700 | 300 | 2,600 | 700 | 3,100 | 800 | 900 | 500 | 3,300 | 1,000 |
| Massachusetts | 30,100 | 4,400 | 200 | 3,500 | 800 | 3,900 | 1,300 | 1,400 | 700 | 4,200 | 1,700 |
| Michigan | 44,100 | 6,700 | 400 | 4,800 | 1,400 | 6,100 | 1,400 | 2,100 | 1,200 | 6,600 | 2,100 |
| Minnesota | 19,900 | 2,800 | 200 | 2,000 | 500 | 2,300 | 700 | 1,100 | 600 | 3,300 | 1,000 |
| Mississippi | 13,200 | 2,000 | 200 | 1,300 | 200 | 1,900 | 400 | 500 | 300 | 2,200 | 300 |
| Missouri | 27,000 | 3,700 | 300 | 2,900 | 800 | 4,000 | 1,100 | 1,100 | 700 | 3,600 | 1,100 |
| Montana | 4,100 | 600 | - | 400 | 100 | 500 | 100 | 200 | 100 | 700 | 200 |
| Nebraska | 7,300 | 1,100 | 100 | 1,000 | 200 | 900 | 200 | 300 | 200 | 1,000 | 300 |
| Nevada | 8,300 | 1,000 | 100 | 900 | 200 | 1,200 | 400 | 300 | 200 | 1,200 | 400 |
| New Hampshire | | 700 | = | 600 | 100 | 700 | 200 | 300 | 100 | 700 | 300 |
| New Jersey | 40,000 | 6,400 | 400 | 4,600 | 1,500 | 4,800 | 1,700 | 1,900 | 1,000 | 5,600 | 2,100 |
| New Mexico | 6,600 | 1,000 | 100 | 700 | 200 | 700 | 300 | 300 | 200 | 1,200 | 200 |
| New York | 81,500 | 13,700 | 1,000 | 9,200 | 3,200 | 9,800 | 2,600 | 3,800 | 1,900 | 11,800 | 4,100 |
| North Carolina | 35,700 | 5,200 | 400 | 3,700 | 1,100 | 5,200 | 1,300 | 1,400 | 900 | 5,300 | 1,400 |
| North Dakota | 3,000 | 500 | _ | 400 | 100 | 300 | 100 | 100 | 100 | 500 | 100 |
| Ohio | 56,100 | 8,600 | 600 | 6,200 | 2,000 | 7,800 | 1,900 | 2,700 | 1,500 | 7,800 | 2,500 |
| Oklahoma | 16,100 | 2,400 | 200 | 1,700 | 300 | 2,500 | 700 | 700 | 500 | 2,100 | 700 |
| Oregon | 15,800 | 2,200 | 100 | 1,600 | 400 | 2,200 | 700 | 700 | 400 | 2,700 | 700 |
| Pennsylvania | 66,600 | 10,500 | 600 | 7,800 | 2,200 | 8,600 | 2,400 | 3,000 | 1,700 | 10,000 | 3,100 |
| Rhode Island | 5,400 | 800 | 100 | 600 | 100 | 800 | 200 | 300 | 100 | 700 | 300 |
| South Carolina | 18,000 | 2,600 | 200 | 1,900 | 500 | 2,500 | 500 | 700 | 500 | 2,900 | 800 |
| South Dakota | 3,500 | 400 | = | 400 | 100 | 400 | 200 | 200 | 100 | 600 | 100 |
| Tennessee | 27,300 | 3,800 | 400 | 2,900 | 600 | 4,200 | 1,300 | 1,200 | 700 | 3,600 | 900 |
| Texas | 76,100 | 11,500 | 1,000 | 8,300 | 2,100 | 10,700 | 3,400 | 3,600 | 2,200 | 11,300 | 2,800 |
| Utah | 5,100 | 900 | 100 | 600 | 200 | 400 | 400 | 300 | 100 | 1,200 | 200 |
| Vermont | 2,700 | 400 | 100 | 400 | 100 | 400 | 200 | 100 | 100 | 300 | 100 |
| Virginia | 29,300 | 4,500 | 300 | 2,900 | 1,000 | 4,000 | 1,200 | 1,200 | 700 | 4,400 | 1,100 |
| Washington | 23,600 | 3,500 | 200 | 2,300 | 600 | 3,100 | 1,100 | 1,100 | 600 | 3,200 | 1,000 |
| West Virginia | 10,500 | 1,400 | 100 | 1,100 | 300 | 1,600 | 400 | 400 | 300 | 1,300 | 400 |
| Wisconsin | 23,600 | 3,300 | 200 | 2,500 | 700 | 2,800 | 1,000 | 1,200 | 700 | 3,800 | 1,200 |
| Wyoming | 2,000 | 300 | | 300 | 100 | 200 | 100 | 100 | 100 | 400 | |
| United States† | 1,220,100 | 182,800 | 12,800 | 130,200 | 36,100 | 164,100 | 47,700 | 54,900 | 31,200 | 180,400 | 53,200 |

⁻ Estimate is 50 or fewer cases. State case estimates between 51 and 99 were rounded to 100.

^{*} Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

[†] State estimates may not add up to United States total due to rounding.

Table 4 Estimated Cancer Mortality by Site and State, US, 2000*

| | | | Estimated Number of Deaths | | | | | | | | | |
|--------------------------|----------------------------|--------------|----------------------------|-------------------|------------|------------|--------------------|-----------------------|------------|--------------|--------------|----------------|
| | Reported | All | Familia | 0-1 0 | | | Lower O | Non- | | | | |
| State | Death Rate per 100,000† | All Sites | Female Breast | Colon & Rectum | Liver | Leukemia | Lung & Bronchus | Hodgkin's Lymphoma | Ovary | Pancreas | Prostate | Stomach |
| Alabama | 179 | 9,700 | 600 | 800 | 300 | 300 | 2,800 | 400 | 200 | 500 | 600 | 200 |
| Alaska | 167 | 700 | 100 | 100 | s | - | 200 | s | - | - | _ | - |
| Arizona | 155 | 9,200 | 600 | 900 | 200 | 300 | 2,600 | 400 | 200 | 500 | 600 | 200 |
| Arkansas | 181 | 6,200 | 400 | 600 | 200 | 200 | 2,100 | 300 | 200 | 300 | 400 | 100 |
| California | 156 | 51,200 | 4,000 | 4,900 | 1,700 | 2,100 | 13,400 | 2,500 | 1,400 | 2,700 | 2,900 | 1,500 |
| Colorado | 142 | 6,100 | 400 | 600 | 100 | 300 | 1,400 | 300 | 100 | 300 | 300 | 100 |
| Connecticut | 163 | 7,000 | 500 | 600 | 200 | 300 | 1,900 | 300 | 200 | 400 | 400 | 200 |
| Delaware | 195 | 1,800 | 100 | 200 | 3. | 100 | 500 | 100 | _ | 100 | 100 | () |
| Dist. of Col. | 212 | 1,200 | 100 | 100 | 10- | | 300 | 1 | - | 100 | 100 | 100 |
| Florida | 166 | 39,900 | 2,700 | 3,900 | 1,000 | 1,500 | 12,000 | 1,900 | 900 | 2,100 | 2,400 | 900 |
| Georgia | 175 | 13,300 | 1,000 | 1,200 | 300 | 500 | 4,000 | 500 | 400 | 600 | 800 | 300 |
| Hawaii | 133 | 2,000 | 100 | 200 | 100 | 100 | 500 | 100 | | 100 | 100 | 100 |
| Idaho | 148 | 2,100 | 200 | 200 | 10000000 | 100 | 500 | 100 | 100 | 100 | 100 | _ |
| Illinois | 178 | 24,900 | 2,000 | 2,600 | 700 | 1,000 | 6,900 | 1,200 | 700 | 1,300 | 1,400 | 600 |
| Indiana | 178 | 12,600 | 900 | 1,300 | 300 | 500 | 3,900 | 600 | 300 | 600 | 700 | 200 |
| lowa | 160 | 6,400 | 500 | 800 | 100 | 300 | 1,800 | 300 | 200 | 300 | 400 | 100 |
| Kansas | 159 | 5,400 | 400 | 500 | 100 | 200 | 1,600 | 200 | 100 | 300 | 300 | 100 |
| Kentucky | 192 | 9,300 | 600 | 900 | 200 | 300 | 3,200 | 400 | 200 | 400 | 500 | 200 |
| Louisiana | 193 | 9,400 | 700 | 1,000 | 300 | 400 | 2,700 | 400 | 200 | 500 | 600 | 300 |
| Maine | 185 | 3,100 | 200 | 300 | _ | 100 | 900 | 200 | 100 | 200 | 200 | 100 |
| Maryland | 184 | 10,200 | 800 | 1,100 | 200 | 400 | 2,900 | 400 | 200 | 500 | 600 | 300 |
| Massachusetts | 178 | 13,600 | 1,000 | 1,500 | 300 | 500 | 3,700 | 700 | 300 | 700 | 700 | 300 |
| Michigan | 173 156 | 20,000 | 1,500 600 | 2,100 900 | 500 200 | 700 400 | 5,800 | 1,000 500 | 500 200 | 1,000 500 | 1,200 600 | 400 200 |
| Minnesota Mississippi | 182 | 6,000 | 400 | 600 | 200 | 200 | 2,200 1,800 | 200 | 100 | 300 | 400 | 100 |
| Missouri | 176 | 12.200 | 800 | 1,300 | 300 | 500 | 3,800 | 500 | 300 | 500 | 600 | 300 |
| Montana | 159 | 1,900 | 100 | 200 | 100 | 100 | 500 | 100 | 100 | 100 | 100 | 300 |
| Nebraska | 155 | 3,300 | 300 | 400 | 100 | 200 | 900 | 200 | 100 | 100 | 200 | 100 |
| Nevada | 184 | 3,800 | 200 | 400 | 100 | 100 | 1,200 | 200 | 100 | 200 | 200 | 100 |
| New Hampshire | 2011000000 | 2.500 | 200 | 300 | 100 | 100 | 700 | 100 | 100 | 100 | 100 | 100 |
| New Jersev | 179 | 18,100 | 1.400 | 2.000 | 500 | 800 | 4.600 | 900 | 500 | 1.000 | 1,000 | 500 |
| New Mexico | 146 | 3.000 | 200 | 300 | 100 | 100 | 700 | 100 | 100 | 100 | 200 | 100 |
| New York | 169 | 36,900 | 3,100 | 4.000 | 900 | 1,400 | 9.400 | 1.800 | 1.000 | 2.200 | 2.100 | 1.100 |
| North Carolina | 175 | 16,200 | 1,200 | 1,600 | 300 | 600 | 5,000 | 700 | 400 | 800 | 900 | 300 |
| North Dakota | 155 | 1,300 | 100 | 200 | _ | 100 | 300 | 100 | _ | 100 | 100 | _ |
| Ohio | 180 | 25,400 | 1.900 | 2.700 | 500 | 1.000 | 7.400 | 1,300 | 600 | 1.300 | 1.400 | 500 |
| Oklahoma | 170 | 7,300 | 500 | 700 | 200 | 300 | 2,400 | 300 | 200 | 300 | 400 | 100 |
| Oregon | 166 | 7,100 | 500 | 700 | 100 | 300 | 2,100 | 300 | 200 | 400 | 500 | 100 |
| Pennsylvania | 177 | 30,100 | 2,300 | 3,400 | 700 | 1,200 | 8,200 | 1,400 | 800 | 1,500 | 1,800 | 600 |
| Rhode Island | 178 | 2,400 | 200 | 300 | 100 | 100 | 800 | 100 | 100 | 100 | 100 | 100 |
| South Carolina | 178 | 8,200 | 600 | 800 | 200 | 300 | 2,400 | 300 | 200 | 400 | 500 | 200 |
| South Dakota | 155 | 1,600 | 100 | 200 | 9 | 100 | 400 | 100 | _ | 100 | 100 | _ |
| Tennessee | 181 | 12,400 | 900 | 1,200 | 300 | 400 | 4.000 | 600 | 300 | 600 | 600 | 300 |
| Texas | 168 | 34,400 | 2,600 | 3,600 | 1,100 | 1,400 | 10,300 | 1,700 | 900 | 1,700 | 2,000 | 900 |
| Utah | 122 | 2,300 | 200 | 200 | 100 | 100 | 400 | 100 | 100 | 100 | 200 | 40 |
| Vermont | 172 | 1,200 | 100 | 200 | _ | _ | 400 | 100 | _ | _ | 100 | - |
| Virginia | 177 | 13,300 | 1,000 | 1,300 | 300 | 500 | 3,800 | 600 | 300 | 600 | 800 | 300 |
| Washington | 162 | 10,700 | 800 | 1,000 | 300 | 500 | 3,000 | 500 | 300 | 500 | 600 | 200 |
| West Virginia | 184 | 4,800 | 300 | 500 | 100 | 200 | 1,500 | 200 | 100 | 200 | 200 | 100 |
| Wisconsin | 163 | 10,700 | 700 | 1,100 | 200 | 500 | 2,700 | 600 | 300 | 600 | 700 | 200 |
| Wyoming | 157 | 900 | 100 | 100 | _ | <u> </u> | 200 | 9_0 | | <u> </u> | 100 | 12_5 |
| United States‡ | | 552,200 | 40,800 | 56,300 | 13,800 | 21,700 | 156,900 | 26,100 | 14,000 | 28,200 | 31,900 | 13,000 |

⁻ Estimate is 50 or fewer deaths. State death estimates between 51 and 99 were rounded to 100.


* Excludes in situ carcinomas except urinary bladder.

† Average annual mortality rate between 1992 and 1996, age-adjusted to the 1970 US standard population.

Source: US Mortality 1992-1996, National Center for Health Statistics, Centers for Disease Control and Prevention 1999, Surveillance, Epidemiology, and End Results Program, Division of Cancer Control and Population Sciences, National Cancer Institute.3

[‡] State estimates may not add up to United States total due to rounding.

Figure 1 Estimated New Cancer Cases* 10 Leading Sites by Gender, US, 2000



^{*}Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Percentages may not total 100% due to rounding.


Estimated Cancer Deaths* 10 Leading Sites by Gender, US, 2000 Lung & Bronchus 31% Lung & Bronchus 25% 15% Prostate 11% Breast Colon & Rectum 10% 11% Colon & Rectum **Pancreas** 5% 5% Pancreas Non-Hodgkin's Lymphoma 5% 5% **Ovary** Leukemia 4% 5% Non-Hodgkin's Lymphoma Esophagus 3% 4% Leukemia Liver & Intrahepatic Bile Duct 2% **Uterine Corpus** 3% Urinary Bladder Brain & Other Nervous System 3% 2% Stomach 3% 2% Stomach† 2% Multiple Myelomat All Other Sites 21% All Other Sites 22%

Figure 2

^{*}Excludes in situ carcinomas except urinary bladder.

[†]These two cancers both received a ranking of 10; they have the same projected number of deaths and contribute the same percentage. Percentages may not total 100% due to rounding.

| Prok | ability of D | Table 5 Probability of Developing Invasive Cancers Over Selected Age Intervals, by Gender, US, 1994-1996* | Table 5 ing Invasive Cancers Over Sel by Gender, US, 1994·1996* | ected Age Interva | ls, |
|---|---|--|---|---|-------------------------|
| | | Birth to 39 (%) | 40 to 59 (%) | 60 to 79 (%) | Birth to Death (%) |
| All sites† | Male | 1.61 (1 in 62) | 8.17 (1 in 12) | 33.65 (1 in 3) | 43.56 (1 in 2) |
| | Female | 1.94 (1 in 52) | 9.23 (1 in 11) | 22.27 (1 in 4) | 38.11 (1 in 3) |
| Breast | Female | 0.43 (1 in 235) | 4.06 (1 in 25) | 6.88 (1 in 15) | 12.56 (1 in 8) |
| Colon & Rectum | Male | 0.06 (1 in 1,579) | 0.85 (1 in 124) | 3.97 (1 in 29) | 5.64 (1 in 18) |
| | Female | 0.05 (1 in 1,947) | 0.67 (1 in 149) | 3.06 (1 in 33) | 5.55 (1 in 18) |
| Lung & Bronchus | Male | 0.04 (1 in 2,592) | 1.29 (1 in 78) | 6.35 (1 in 16) | 8.11 (1 in 12) |
| | Female | 0.03 (1 in 2,894) | 0.94 (1 in 106) | 3.98 (1 in 25) | 5.69 (1 in 18) |
| Prostate | Male | (Less than 1 in 10,000) | 1.90 (1 in 53) | 13.69 (1 in 7) | 15.91 (1 in 6) |
| *Of those free of cancer at beginning of The "1 in" statistic and the inverse of the †Excludes basal and squamous cell skill Source: Survelllance, Epidemiology, and Version 4.0, National Cancer Institute. ⁶ | eginning of age inte inverse of the percei ous cell skin cancers niology, and End Rec Institute. ⁶ | ***Of those free of cancer at beginning of age interval and based on cancer cases diagnosed between 1994 and 1996. The "1 in" statistic and the inverse of the percentage may not be equivalent due to rounding. Exclusion as a sasal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Surveillance, Epidemiology, and End Results Program, 1973-1996, Division of Cancer Control and Population Sciences, National Cancer Institute, DEVCAN Software, Version 4.0, National Cancer Institute. | gnosed between 1994 and 1996 rounding, rary bladder. of Cancer Control and Populatio | o. n Sciences, National Cancer Insti | itule, DEVCAN Software, |



CA—A CANCER JOURNAL FOR CLINICIANS




Table 6 Reported Deaths for the 10 Leading Causes of Death by Age and Gender, US, 1997

| | All Ages | | Ages 1- | 19 | Ages 20- | 39 |
|-----|---|---|--|--|---|---|
| | Male | Female | Male | Female | Male | Female |
| | All Causes 1,154,039 | All Causes 1,160,206 | All Causes 18,149 | All Causes 9,685 | All Causes 69,832 | All Causes 31,150 |
| 1. | Heart Diseases 356,598 | Heart Diseases 370,376 | Accidents 7,882 | Accidents 4,097 | Accidents 20,240 | Accidents 6,463 |
| 2. | Cancer 281,110 | Cancer 258,467 | Homicide 2,740 | Cancer 963 | Suicide 9,426 | Cancer 6,159 |
| 3. | Cerebro- vascular Diseases 62,564 | Cerebro- vascular Diseases 97,227 | Suicide 1,723 | Homicide 710 | Homicide 8,669 | Heart Diseases 2,794 |
| 4. | Accidents 61,963 | Chronic Obstructive Pulmonary Diseases 53,045 | Cancer 1,207 | Congenital Anomalies 570 | HIV Infection 5,994 | Suicide 2,037 |
| 5. | Chronic Obstructive Pulmonary Diseases 55,984 | Pneumonia & Influenza 47,165 | Congenital Anomalies 683 | Suicide 386 | Heart Diseases 5,833 | Homicide 2,001 |
| 6. | Pneumonia & Influenza 39,284 | Diabetes Mellitus 34,449 | Heart Diseases 557 | Heart Diseases 385 | Cancer 5,467 | HIV Infection 1,918 |
| 7. | Diabetes Mellitus 28,187 | Accidents 33,681 | Cerebral Palsy 241 | Pneumonia & Influenza 200 | Cirrhosis of Liver 1,149 | Cerebro- vascular Diseases 878 |
| 8. | Suicide 24,492 | Alzheimer's Disease 15,437 | Pneumonia & Influenza 215 | Cerebral Palsy 186 | Cerebro- vascular Diseases 878 | Diabetes Mellitus 619 |
| 9. | Cirrhosis of Liver 16,260 | Nephritis 13,191 | Chronic Obstructive Pulmonary Diseases 165 | Benign Neoplasms 103 | Diabetes Mellitus 842 | Cirrhosis of Liver 571 |
| 10. | Homicide 15,449 | Septicemia 12,741 | Peripheral Nervous System Diseases 148 | Chronic Obstructive Pulmonary Diseases 101 | Pneumonia & Influenza 730 | Pneumonia & Influenza 505 |

Source: US Mortality Public Use Data Tape 1997_{ι} National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

Table 6 (Continued)

| Ages 40-59 | | Ages 60 | -79 | Ages 8 | Ages 80+ | | |
|--|--|---|---|---|---|--|--|
| Male | Female | Male | Female | Male | Female | | |
| All Causes 182,834 | All Causes 111,414 | All Causes 513,377 | All Causes 410,559 | All Causes 353,742 | All Causes 585,057 | | |
| Heart Diseases 51,356 | Cancer 45,781 | Heart Diseases 168,426 | Cancer 131,274 | Heart Diseases 130,028 | Heart Diseases 231,179 | | |
| Cancer 47,118 | Heart Diseases 19,744 | Cancer 161,581 | Heart Diseases 115,982 | Cancer 65,685 | Cancer 74,240 | | |
| Accidents 15,507 | Accidents 5,779 | Chronic Obstructive Pulmonary Diseases 31,528 | Cerebro- vascular Diseases 27,798 | Cerebro- vascular Diseases 28,609 | Cerebro- vascular Diseases 63,175 | | |
| Cirrhosis of Liver 7,642 | Cerebro- vascular Diseases 5,175 | Cerebro- vascular Diseases 26,491 | Chronic Obstructive Pulmonary Diseases 27,501 | Pneumonia & Influenza 21,773 | Pneumonia & Influenza 34,046 | | |
| Suicide 7,568 | Diabetes Mellitus 4,032 | Diabetes Mellitus 15,082 | Diabetes Mellitus 16,310 | Chronic Obstructive Pulmonary Diseases 20,368 | Chronic Obstructive Pulmonary Diseases 21,682 | | |
| Cerebro- vascular Diseases 6,295 | Chronic Obstructive Pulmonary Diseases 3,372 | Pneumonia & Influenza 13,576 | Pneumonia & Influenza 10,443 | Diabetes Mellitus 7,302 | Diabetes Mellitus 13,453 | | |
| HIV Infection 6,109 | Cirrhosis of Liver 2,814 | Accidents 10,650 | Accidents 7,145 | Accidents 7,163 | Alzheimer's Disease 12,215 | | |
| Diabetes Mellitus 4,921 | Suicide 2,405 | Diseases of Arteries 8,289 | Diseases of Arteries 5,300 | Nephritis 5,599 | Accidents 9,853 | | |
| Chronic Obstructive Pulmonary Diseases 3,478 | Pneumonia & Influenza 1,805 | Cirrhosis of Liver 6,461 | Nephritis 4,624 | Diseases of Arteries 5,044 | Atherosclerosis 8,017 | | |
| Homicide | HIV Infection 1,446 | Nephritis 5,136 | Cirrhosis of Liver | Alzheimer's Disease | Nephritis 7,530 | | |

Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

| | Fifteen Lead | Table 7 ing Causes of | Death, US, 1997 | |
|------|---|--------------------------|--|------------------------------------|
| Rank | Cause of Death | Number of Deaths | Death Rate per 100,000 Population* | Percent (%) of Total Deaths† |
| | All Causes | 2,314,245 | 654.3 | 100.0 |
| 1 | Heart Diseases | 726,974 | 194.6 | 31.4 |
| 2 | Cancer | 539,577 | 164.1 | 23.3 |
| 3 | Cerebrovascular Diseases | 159,791 | 40.8 | 6.9 |
| 4 | Chronic Obstructive Pulmonary Diseases | 109,029 | 30.6 | 4.7 |
| 5 | Accidents | 95,644 | 31.5 | 4.1 |
| 6 | Pneumonia & Influenza | 86,449 | 21.2 | 3.7 |
| 7 | Diabetes Mellitus | 62,636 | 18.3 | 2.7 |
| 8 | Suicide | 30,535 | 10.2 | 1.3 |
| 9 | Diseases of Arteries | 27,792 | 7.7 | 1.2 |
| 10 | Nephritis | 25,331 | 6.7 | 1.1 |
| 11 | Cirrhosis of Liver | 25,175 | 8.2 | 1.1 |
| 12 | Alzheimer's Disease | 22,475 | 5.2 | 1.0 |
| 13 | Septicemia | 22,396 | 6.1 | 1.0 |
| 14 | Homicide | 19,846 | 7.3 | 0.9 |
| 15 | HIV Infection | 16,516 | 5.0 | 0.7 |
| | Other & III-defined | 344,079 | | 14.9 |

^{*}Age-adjusted to the 1970 US standard population. †Percentages may not total 100% due to rounding. Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

| Rep | | | e 8 ive Leading ge, US, 199 | | s |
|-------------------------------------|---------------------------------|----------------------------------|------------------------------------|------------------------------------|------------------------------|
| All Ages | < 20 | 20-39 | 40-59 | 60-79 | ≥80 |
| All Sites 281,110 | All Sites 1,252 | All Sites 5,467 | All Sites 47,118 | All Sites 161,581 | All Sites 65,685 |
| Lung & Bronchus 91,278 | Leukemia 423 | Non-Hodgkin's Lymphoma 723 | Lung & Bronchus 15,379 | Lung & Bronchus 59,558 | Lung & Bronchus 15,823 |
| Prostate 32,891 | Brain & ONS 288 | Leukemia 662 | Colon & Rectum 4,347 | Prostate 16,277 | Prostate 15,511 |
| Colon & Rectum 28,075 | Endocrine System 115 | Brain & ONS 625 | Pancreas 2,584 | Colon & Rectum 15,842 | Colon & Rectum 7,459 |
| Pancreas 13,470 | Bones & Joints 86 | Lung & Bronchus 512 | Non-Hodgkin's Lymphoma 2,552 | Pancreas 7,898 | Urinary Bladder 2,900 |
| Non-Hodgkin's Lymphoma 12,286 | Non-Hodgkin's Lymphoma 86 | Colon & Rectum 412 | Esophagus 2,069 | Non-Hodgkin's Lymphoma 6,383 | Pancreas 2,843 |

Note: "All Sites" excludes in situ carcinomas except urinary bladder.

ONS = other nervous system.

Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

| Table 9 Reported Deaths for the Five Leading Cancer Sites for Females by Age, US, 1997 | | | | | | | | |
|--|---------------------------|---------------------------|------------------------------|------------------------------|------------------------------------|--|--|--|
| All Ages | < 20 | 20-39 | 40-59 | 60-79 | ≥80 | | | |
| All Sites 258,467 | All Sites 1,009 | All Sites 6,159 | All Sites 45,781 | All Sites 131,274 | All Sites 74,240 | | | |
| Lung & Bronchus 61,922 | Leukemia 322 | Breast 1,629 | Breast 12,093 | Lung & Bronchus 38,488 | Lung & Bronchus 12,879 | | | |
| Breast 41,943 | Brain & ONS 253 | Uterine Cervix 629 | Lung & Bronchus 10,088 | Breast 18,385 | Colon & Rectum 12,046 | | | |
| Colon & Rectum 28,621 | Soft Tissue 85 | Lung & Bronchus 462 | Colon & Rectum 3,426 | Colon & Rectum 12,799 | Breast 9,835 | | | |
| Pancreas 14,205 | Endocrine System 79 | Leukemia 462 | 0vary 2,801 | Pancreas 7,437 | Pancreas 5,045 | | | |
| 0vary 13,507 | Bones & Joints 71 | Brain & ONS 385 | Uterine Cervix 1,803 | Ovary 7,207 | Non-Hodgkin's Lymphoma 3,859 | | | |

Note: "All Sites" excludes in situ carcinomas except urinary bladder.

ONS = other nervous system.

Source: US Mortality Públic Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

Table 10 Incidence and Mortality Rates* by Site, Race, and Ethnicity, US, 1990-1996

Black

White

Site

Asian/Pacific

Islander

American

Indian

Hispanic†

| | | INCIDE | NCE | | |
|-----------------|-------|--------|-------|-------|-------|
| All Sites | | | | | |
| Total | 402.9 | 442.9 | 279.1 | 153.4 | 275.4 |
| Male | 480.2 | 598.0 | 325.5 | 177.8 | 326.9 |
| Female | 351.6 | 335.6 | 244.9 | 136.8 | 243.2 |
| Breast Female) | 113.2 | 99.3 | 72.6 | 33.9 | 69.4 |
| Colon & Rectum | | | | | |
| Total | 43.9 | 50.4 | 38.6 | 16.4 | 29.0 |
| Male | 53.2 | 58.1 | 47.5 | 21.5 | 35.7 |
| Female | 36.8 | 44.9 | 31.4 | 12.4 | 24.0 |
| Lung & Bronchus | | | | | |
| Total | 55.9 | 73.9 | 35.8 | 18.6 | 27.6 |
| Male | 73.1 | 112.3 | 52.4 | 25.3 | 38.8 |
| Female | 43.3 | 46.2 | 22.5 | 13.5 | 19.6 |
| Prostate | 147.3 | 222.9 | 81.5 | 46.5 | 102.8 |
| | | MORTA | LITY | | |
| All Sites | | | | | |
| Total | 167.5 | 223.4 | 103.4 | 104.0 | 104.9 |
| Male | 208.8 | 308.8 | 129.2 | 123.3 | 131.8 |
| Female | 139.8 | 168.1 | 83.5 | 90.2 | 86.3 |
| Breast (Female) | 25.7 | 31.4 | 11.4 | 12.3 | 15.3 |
| Colon & Rectum | | | | | |
| Total | 17.4 | 23.1 | 10.9 | 9.9 | 10.4 |
| Male | 21.5 | 27.8 | 13.4 | 11.0 | 13.2 |
| Female | 14.5 | 20.0 | 9.0 | 8.9 | 8.4 |
| Lung & Bronchus | | | | | |
| Total | 49.3 | 60.5 | 23.7 | 28.8 | 19.9 |
| Male | 70.1 | 100.8 | 34.9 | 40.5 | 32.0 |
| Female | 33.8 | 32.8 | 14.9 | 19.8 | 11.0 |

Note: Incidence data are from the 11 SEER areas; mortality data are from all states except Connecticut, Oklahoma, Louisiana, and New Hampshire.

54.8

23.7

10.7

14.3

16.7

Prostate

^{*}Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.

[†]Hispanic is not mutually exclusive of white, black, Asian/Pacific Islander, or American Indian.

Sources: Surveillance, Epidemiology, and End Results Program 1973-1996, Division of Cancer Control and Population Sciences, National Cancer Institute³ (Incidence); US Mortality 1973-1996, National Center for Health Statistics, Centers for Disease Control and Prevention 1999, Surveillance, Epidemiology, and End Results Program, Division of Cancer Control and Population Sciences, National Cancer Institute³ (Mortality).

| Table 11 | |
|---|--|
| Trends in Five-Year Relative Cancer Survival Rates* (%) | |
| by Race and Year of Diagnosis, US, 1974-1995 | |

| | 1974- 1976 | 1980- 1982 | 1989- 1995 | 1974- 1976 | 1980- 1982 | 1989- 1995 | 1974- 1976 | 1980- 1982 | 1989- 1995 |
|------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Site | | White | | | Black | | | All Race | S |
| All Sites | 51 | 52 | 61† | 39 | 40 | 48† | 50 | 51 | 59† |
| Brain | 22 | 25 | 30† | 27 | 31 | 39† | 22 | 25 | 30† |
| Breast (Female) | 75 | 77 | 86† | 63 | 66 | 71† | 75 | 76 | 85† |
| Colon | 51 | 56 | 62† | 46 | 49 | 52† | 50 | 55 | 62† |
| Esophagus | 5 | 7 | 13† | 4 | 5 | 9† | 5 | 7 | 12† |
| Hodgkin's Disease | 72 | 75 | 83† | 69 | 72 | 76 | 71 | 75 | 82† |
| Kidney | 52 | 51 | 61† | 49 | 55 | 58† | 52 | 52 | 60† |
| Larynx | 66 | 69 | 66 | 60 | 58 | 53 | 66 | 68 | 65 |
| Leukemia | 35 | 39 | 44† | 31 | 33 | 34 | 34 | 39 | 43† |
| Liver | 4 | 4 | 6† | 2 | 2 | 3 | 4 | 4 | 5† |
| Lung & Bronchus | 13 | 14 | 14† | 12 | 12 | 11 | 13 | 13 | 14† |
| Melanoma of Skin | 80 | 83 | 88† | 67‡ | 61§ | 68‡ | 80 | 83 | 88† |
| Multiple Myeloma | 24 | 28 | 28† | 28 | 29 | 31 | 24 | 28 | 28† |
| Non-Hodgkin's Lymphoma | 48 | 52 | 52† | 48 | 50 | 41† | 47 | 51 | 51† |
| Oral Cavity & Pharynx | 55 | 55 | 56 | 36 | 31 | 34 | 53 | 53 | 53 |
| Ovary | 37 | 39 | 50† | 41 | 39 | 47† | 37 | 39 | 50† |
| Pancreas | 3 | 3 | 4† | 3 | 5 | 4† | 3 | 3 | 4† |
| Prostate | 68 | 75 | 93† | 58 | 65 | 84† | 67 | 73 | 92† |
| Rectum | 49 | 53 | 60† | 42 | 38 | 51† | 49 | 52 | 60† |
| Stomach | 15 | 17 | 19† | 17 | 19 | 22 | 15 | 18 | 21† |
| Testis | 79 | 92 | 96† | 76‡ | 90‡ | 88 | 79 | 92 | 95† |
| Thyroid | 92 | 94 | 95† | 88 | 94 | 89 | 92 | 94 | 95† |
| Urinary bladder | 74 | 79 | 82† | 48 | 58 | 62† | 73 | 78 | 81† |
| Uterine Cervix | 70 | 68 | 71† | 64 | 61 | 59 | 69 | 67 | 70 |
| Uterine Corpus | 89 | 83 | 86† | 61 | 54 | 56 | 88 | 82 | 84† |


*Survival rates are adjusted for normal life expectancy and are based on follow-up of patients through 1996.

[†]The difference in rates between 1974-1976 and 1989-1995 is statistically significant (p < 0.05).

[‡]The standard error of the survival rate is between five and 10 percentage points.

[§]The standard error of the survival rate is greater than 10 percentage points.

Source: Surveillance, Epidemiology and End Results Program 1973-1996, Division of Cancer Control and Population Sciences, National Cancer Institute.³



Note: Due to changes in the ICD coding, numerator information has changed over time. Rates for cancer of the uterus, ovary, lung & bronchus, and colon & rectum are affected by these coding changes.

1960

Year

1970

1950

1980

1990


1930

1940

^{*} Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.

[†] Uterine cancer death rates are for uterine cervix and uterine corpus combined.


Source: US Mortality Public Use Data Tapes 1960-1996, US Mortality Volumes 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.



Note: Due to changes in the ICD coding, numerator information has changed over time. Rates for cancer of the liver, lung & bronchus, and colon & rectum are affected by these coding changes.

Source: US Mortality Public Use Data Tapes 1960-1996, US Mortality Volumes 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

^{*} Rates are per 100,000 population and are age-adjusted to the 1970 US standard population.






Table 12 Fifteen Leading Causes of Death Among Children Aged 1-14 Years, US, 1997

| Rank | Cause of Death | Number of Deaths | Death Rate per 100,000 Population* | Percent (%) of Total Deaths† |
|------|--|------------------------|--|------------------------------------|
| | All Causes | 13,562 | 24.6 | 100.0 |
| 1 | Accidents | 5,376 | 9.8 | 39.6 |
| 2 | Cancer | 1,468 | 2.7 | 10.8 |
| 3 | Congenital Anomalies | 1,036 | 1.8 | 7.6 |
| 4 | Homicide | 832 | 1.5 | 6.1 |
| 5 | Heart Diseases | 525 | 1.0 | 3.9 |
| 6 | Pneumonia & Influenza | 321 | 0.6 | 2.4 |
| 7 | Cerebral Palsy | 313 | 0.6 | 2.3 |
| 8 | Suicide | 307 | 0.6 | 2.3 |
| 9 | Chronic Obstructive Pulmonary Diseases | 170 | 0.3 | 1.3 |
| 10 | HIV Infection | 156 | 0.3 | 1.2 |
| 11 | Benign Neoplasms | 141 | 0.3 | 1.0 |
| 12 | Cerebrovascular Diseases | 132 | 0.2 | 1.0 |
| 13 | Septicemia | 125 | 0.2 | 0.9 |
| 14 | Viral Diseases | 107 | 0.2 | 8.0 |
| 15 | Anemias | 103 | 0.2 | 8.0 |
| | All Others | 2,450 | | 18.1 |

^{*} Age-adjusted to the 1970 US standard population.

[†] Percentages may not total 100% due to rounding.

Source: US Mortality Public Use Data Tape 1997, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999.

| | | Table | 13 | | | |
|-----------|------------|----------|---------|-----------|--------|-----|
| Trends in | Five-Year | Relative | Cancer | Survival | Rates* | (%) |
| for | Children U | Jnder Aa | e 15, U | S. 1974-1 | 995 | |

| | | Five- | Year Relative | Survival Rates | (%) | |
|------------------------------|---------------|---------------|---------------|----------------|---------------|---------------|
| | | | Year of D | iagnosis | | |
| Site | 1974- 1976 | 1977- 1979 | 1980- 1982 | 1983- 1985 | 1986- 1988 | 1989- 1995 |
| All Sites | 56 | 62 | 65 | 68 | 70 | 75† |
| Acute Lymphocytic Leukemia | 53 | 67 | 71 | 69 | 78 | 81† |
| Acute Myeloid Leukemia | 14 | 28‡ | 21‡ | 32‡ | 32‡ | 43† |
| Bones and Joints | 53‡ | 53‡ | 54‡ | 57‡ | 62‡ | 67† |
| Brain & Other Nervous System | 55 | 56 | 55 | 62 | 62 | 64† |
| Hodgkin's Disease | 78 | 84 | 91 | 90 | 90 | 93† |
| Neuroblastoma | 53 | 54 | 53 | 55 | 59 | 71† |
| Non-Hodgkin's Lymphoma | 44 | 51 | 61 | 71 | 70 | 77† |
| Soft Tissue | 61 | 69 | 65 | 76 | 66 | 77† |
| Wilms' Tumor | 74 | 78 | 87 | 86 | 91 | 93† |

Note: "All sites" excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

Source: Surveillance, Epidemiology, and End Results Program 1973-1996, Division of Cancer Control and Population Sciences, National Cancer Institute.³

^{*} Survival rates are adjusted for normal life expectancy and are based on follow-up of patients through 1996.

[†] The difference in rates between 1974-1976 and 1989-1995 is statistically significant (p<0.05).

[‡] The standard error of the survival rate is between five and 10 percentage points.

| Male Female Male Female Female Female Female Female Male Female Male Female Male Female Male Female Male Female Male | | ć | • | | LL . IA/ | - | | Table | le 14 | - | * | , | | c | | | |
|--|----------------------|------------|------------|-----------|----------|-----------|---------------|-----------|-----------|-------------------|------------------|----------------|----------|-----------|----------|----------|----------|
| Male Female Male Female Female Female Female Female Male Female Male Female Male Female Male Female Male Female Male Male Female Male Male Male Female Male Ma | | Can | ser Ar | Duno | rne w | oria: / | rge-A Site | for 4 | 50 De | atn Ha Intries | res p s, 199. | er 10 4-199 | 7,000 | 1001 | lation | | |
| Male Female Male Female Male Female Female Male | Country | All S | ites | ō | al | Colon & | Rectum | Breast | Prostate | II. | Dū | Ή | Uterus | Ston | Stomach | Leukemia | mia |
| 156.0 (24) 108.3 (7) 3.2 (29) 1.1 (23) 15.2 (27) 10.4 (23) 20.0 (14) 15.9 (20) 38.8 (29) 156.7 (22) 98.2 (25) 4.1 (26) 1.2 (12) 20.2 (10) 13.3 (10) 19.9 (15) 19.0 (9) 38.8 (29) 161.0 (21) 99.9 (22) 6.0 (18) 1.1 (27) 21.7 (8) 12.2 (14) 20.9 (13) 16.9 (14) 40.7 (25) 156.0 (28) 86.5 (32) 4.9 (21) 0.8 (39) 17.2 (20) 11.4 (19) 15.9 (31) 8.5 (34) 43.7 (23) 156.2 (23) 106.6 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (42) 0.6 (43) 7.0 (38) 6.7 (36) 12.1 (35) 16.0 (19) 20.5 (39) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) ~ ~ ~ 37.3 (30) 142.5 (32) 105.3 (14) 1.2 (19) 48.8 (44) 5.1 (40) 12.6 (28) 13.0 (25) 142.5 (32) 12.4 (17) 1.2 (19) 48.8 (44) 5.1 (40) 12.6 (28) 12.6 (19) 12.6 (28) 142.5 (32) 12.4 (14) 1.2 (19) 48.8 (44) 5.1 (40) 12.6 (28) 12.6 (19) 12.6 (28) 142.5 (32) 12.4 (14) 1.2 (19) 48.8 (14) 13.2 (10) 14.9 (33) 20.8 (14) 35.7 (31) 142.3 (33) 85.0 (34) 2.2 (39) 1.0 (39) 12.1 (31) 8.5 (31) 16.8 (25) 17.6 (12) 142.3 (33) 85.0 (34) 2.2 (39) 1.0 (39) 12.1 (31) 8.5 (31) 16.8 (25) 17.6 (12) 142.3 (33) 85.0 (34) 1.3 (49) 0.6 (44) 8.0 (35) 6.2 (39) 16.2 (27) 93.3 (39) 16.5 (39) 14.5 (27) 142.3 (33) 83.4 (27) 103.3 (17) 6.5 (15) 12.4 (19) 13.3 (19) 12.4 (19) 13.8 (19) 14.5 (27) 142.1 (36) 12.0 (5) 4.4 (24) 1.3 (8) 12.8 (17) 13.3 (9) 16.1 (21) 13.3 (9) 12.1 (19) 17.5 (19) 17.1 (19) | | Male | Female | Male | Female | Male | Female | Female | Male | Male | Female | Cervix | Other | Male | Female | Male | Female |
| 1567 (22) 882 (25) 4.1 (26) 1.2 (12) 20.2 (10) 13.3 (10) 19.9 (15) 19.0 (9) 88.8 (29) 16.1 (21) 89.9 (22) 6.0 (18) 1.1 (27) 81.2 (14) 20.9 (13) 16.9 (14) 40.7 (26) 15.0 (28) 86.5 (32) 4.9 (21) 0.8 (39) 17.2 (20) 11.4 (19) 15.9 (31) 8.5 (34) 43.7 (23) 156.0 (28) 86.5 (32) 4.9 (21) 0.8 (39) 17.2 (20) 11.4 (19) 15.9 (31) 8.5 (34) 43.7 (23) 156.2 (23) 106.6 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (27) 1.2 (17) 16.1 (26) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (27) 1.2 (17) 16.1 (26) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (24) 11.2 (14) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (36) 11.5 (16) 12.8 (27) 2.2 (37) 11.5 (16) 12.8 (27) 2.2 (37) 11.5 (16) 12.8 (27) 2.2 (37) 11.5 (16) 12.8 (27) 2.2 (37) | United States† | | 108.3 (7) | 3.2 (29) | 1.1 (23) | 15.2 (27) | 10.4 (23) | 20.0 (14) | 15.9 (20) | 52.3 (13) | 26.6 (2) | 2.4 (34) | 2.5 (33) | 4.4 (44) | 2.0 (44) | 6.3 (5) | 3.7 (10) |
| 161.0 (21) 99.9 (22) 6.0 (18) 1.1 (27) 21.7 (8) 12.2 (14) 20.9 (13) 16.9 (14) 40.7 (28) 17.0 (40) 62.8 (45) 2.3 (38) 0.4 (45) 6.0 (41) 4.2 (43) 8.6 (42) 5.1 (41) 22.3 (38) 150.0 (28) 86.5 (32) 4.9 (21) 0.8 (39) 17.2 (20) 11.4 (19) 15.9 (31) 8.5 (34) 43.7 (23) 156.2 (23) 106.6 (13) 3.8 (27) 1.2 (17) 16.1 (29) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (42) 0.6 (43) 7.0 (38) 6.7 (39) 12.1 (35) 16.0 (19) 20.5 (39) 149.9 (29) 83.5 (37) 2.6 (39) 1.1 (24) 7.9 (38) 6.7 (39) 12.1 (35) 16.0 (19) 20.5 (39) 12.2 (14) 1.2 (19) 4.8 (44) 5.1 (40) 12.1 (25) 16.0 (19) 20.5 (39) 12.2 (29) 83.5 (37) 2.6 (39) 1.1 (24) 1.2 (19) 14.3 (44) 2.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.2 (29) 12.3 (29 | Australia‡ | 156.7 (22) | 98.2 (25) | 4.1 (26) | 1.2 (12) | 20.2 (10) | 13.3 (10) | 19.9 (15) | 19.0 (9) | 38.8 (29) | 13.6 (10) | 2.6 (31) | 1.7 (43) | 6.6 (40) | 2.7 (43) | 6.1 (6) | 3.6 (11) |
| 117.0 (40) 62.8 (45) 2.3 (38) 0.4 (45) 6.0 (41) 4.2 (43) 8.6 (42) 5.1 (41) 22.3 (38) 150.0 (28) 865 (32) 4.9 (21) 0.8 (39) 17.2 (20) 11.4 (19) 15.9 (31) 8.5 (34) 43.7 (23) 156.2 (23) 106.6 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 12.1 (35) 16.0 (19) 20.5 (39) 142.5 (32) 106.6 (13) 2.1 (47) 2.1 (21) 16.1 (26) 10.3 (25) 12.1 (35) 16.0 (19) 20.5 (39) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (38) 6.4 (37) 5.0 (44) 2.7 (23) 12.1 (24) 11.2 (19) 4.8 (44) 5.1 (49) 12.1 (25) 13.0 (25) 6.1 (6) 12.2 (25) 11.5 (19) 12.2 (25) 13.0 (25) 6.1 (6) 12.2 (25) 12.2 (25) 11.5 (14) 12.2 (25) 11.5 (14) 12.2 (25) 11.5 (14) 12.2 (25) 12. | Austria† | 161.0 (21) | 99.9 (22) | 6.0 (18) | 1.1 (27) | 21.7 (8) | 12.2 (14) | 20.9 (13) | 16.9 (14) | 40.7 (26) | 10.3 (16) | 2.6 (33) | 4.0 (20) | 12.8 (24) | 6.9 (24) | 4.8 (24) | 3.2 (18) |
| 1562 (23) 1666 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 12.15 (10) 16.4 (17) 50.0 (14) 142.5 (32) 106.6 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 12.15 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (42) 0.6 (43) 7.0 (38) 6.7 (36) 12.1 (35) 16.0 (19) 20.5 (39) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) ~ ~ 37.3 (30) 97.7 (43) 89.1 (29) 2.1 (41) 1.2 (19) 4.8 (44) 5.1 (40) 1.2 (28) 143.5 (44) 2.1 (47) 1.2 (29) 83.7 (31) 12.1 (21) 12.1 (21) 13 | Azerbaijan§ | 117.0 (40) | 62.8 (45) | 2.3 (38) | 0.4 (45) | 6.0 (41) | 4.2 (43) | 8.6 (42) | 5.1 (41) | 22.3 (38) | 3.7 (45) | 1.8 (39) | 3.7 (23) | 24.9 (10) | 9.5 (15) | 3.9 (38) | 2.7 (38) |
| 1562 (23) 1066 (13) 3.8 (27) 1.2 (17) 16.1 (26) 10.3 (25) 21.5 (10) 16.4 (17) 50.0 (14) 142.5 (32) 105.3 (14) 2.1 (42) 0.6 (43) 7.0 (38) 6.7 (36) 12.1 (36) 12.1 (36) 12.0 (39) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) 2.1 (30) 2.1 (41) 1.2 (19) 4.8 (44) 5.1 (40) 9.1 (40) 1.2 (28) 143.3 (39) 2.2 (3) 12.2 (39) 1.3 (29) 2.2 (3) 1.3 (29) 1 | Bulgaria¶ | 150.0 (28) | 86.5 (32) | 4.9 (21) | 0.8 (39) | 17.2 (20) | 11.4 (19) | 15.9 (31) | _ | 43.7 (23) | 6.6 (32) | 4.9 (18) | 5.7 (5) | 18.5 (19) | 8.8 (17) | 4.9 (23) | 3.0 (33) |
| 142.5 (32) 105.3 (14) 2.1 (42) 0.6 (43) 7.0 (38) 6.7 (38) 12.1 (35) 160 (19) 20.5 (39) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) ~~~ 37.3 (30) 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) ~~~ 37.3 (30) 37.7 (43) 89.1 (29) 2.1 (41) 1.2 (19) 4.8 (44) 5.1 (40) 12.6 (29) 14.3 (44) 1.2 (25) 6.1 (6) 1.2 (25) 6.1 (2 | Canada‡ | 156.2 (23) | 106.6 (13) | 3.8 (27) | 1.2 (17) | 16.1 (26) | 10.3 (25) | 21.5 (10) | 16.4 (17) | 50.0 (14) | 23.0 (3) | 1.9 (35) | 2.2 (38) | 6.2 (42) | 3.0 (41) | 5.5 (17) | 3.2 (22) |
| 149.9 (29) 83.5 (37) 2.6 (36) 1.1 (24) 7.9 (36) 6.4 (37) 5.0 (44) ~ ~ ~ 37.3 (30) 97.7 (43) 89.1 (29) 2.1 (41) 1.2 (19) 4.8 (44) 5.1 (40) 9.1 (40) 12.6 (29) 14.3 (44) 212.0 (6) 98.7 (24) 11.4 (4) 1.0 (29) 22.5 (6) 11.5 (18) 18.5 (20) 13.0 (25) 65.1 (6) 127.2 (35) 91.8 (27) 5.5 (20) 1.5 (4) 94.7 (34) 11.3 (20) 14.9 (33) 20.8 (4) 35.7 (31) 128.6 (14) 140.0 (1) 4.5 (23) 1.5 (18) 15.6 (4) 17.3 (2) 12.8 (2) 13.0 (18) 178.6 (14) 140.0 (1) 4.5 (23) 1.5 (18) 15.6 (4) 12.8 (2) 12.8 (2) 142.3 (33) 85.0 (34) 2.2 (39) 1.0 (33) 12.1 (31) 85.5 (31) 16.8 (25) 17.6 (19) 45.4 (20) 142.3 (33) 85.0 (34) 1.3 (44) 0.6 (44) 80.6 (5) 62.3 (6) 19.6 (16) 15.8 (21) 145.7 (31) 78.2 (41) 1.9 (44) 0.6 (44) 80.6 (5) 62.1 (4) 12.0 (30) 17.1 (35) 147.1 (36) 104.5 (15) 1.5 (42) 1.3 (8) 12.8 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.1 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.1 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.1 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.7 (36) 104.5 (15) 1.5 (45) 17.9 (18) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 147.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (17) 11.2 (| Chile¶ | 142.5 (32) | 105.3 (14) | 2.1 (42) | 0.6 (43) | 7.0 (38) | 6.7 (36) | 12.1 (35) | 16.0 (19) | 20.5 (39) | 6.4 (33) | 10.6 (3) | 2.8 (31) | 32.2 (3) | 11.7 (8) | 4.2 (34) | 2.7 (39) |
| 97.7 (43) 89.1 (29) 2.1 (41) 1.2 (19) 4.8 (44) 5.1 (40) 12.6 (28) 14.3 (44) 212.0 (6) 98.7 (24) 11.4 (4) 10 (29) 22.5 (6) 11.5 (18) 18.5 (20) 13.0 (28) 65.1 (6) 12.2 (35) 12.4 (3) 2.2 (3) 12.4 (3) 2.2 (3) 12.4 (3) 2.2 (4) 2.2 (4) 12.6 (2) 12.6 (4) 2.2 (4) 2.2 (3) 12.4 (3) 2.2 (4) 2.2 (| China [®] ¶ | 149.9 (29) | 83.5 (37) | 2.6 (36) | 1.1 (24) | 7.9 (36) | 6.4 (37) | 5.0 (44) | | 37.3 (30) | 15.8 (8) | 3.0 (27) | 3 | 26.9 (6) | 12.7 (4) | 3.7 (40) | 3.0 (31) |
| 212.0 (6) 98.7 (24) 11.4 (4) 10 (29) 22.5 (6) 11.5 (18) 18.5 (20) 13.0 (25) 65.1 (6) 127.2 (35) 91.8 (27) 55.5 (20) 15 (4) 94.6 (4) 11.3 (20) 14.9 (33) 20.8 (4) 35.7 (31) 12.8 (4) 10.0 (1) 4.5 (23) 10.6 (3) 22.7 (5) 15.6 (4) 27.6 (1) 19.9 (6) 49.1 (16) 12.8 (27) 10.8 (31) 10.2 (31) 10.3 (31) 10.1 (31) 10.1 (31) 10.1 (31) 10.2 (31) 10.8 (31) 10. | Colombia¶ | 97.7 (43) | 89.1 (29) | 2.1 (41) | 1.2 (19) | 4.8 (44) | 5.1 (40) | 9.1 (40) | 12.6 (28) | 14.3 (44) | 6.8 (30) | 9.9 (5) | 4.5 (16) | 21.4 (13) | 13.1 (3) | 4.3 (33) | 3.7 (9) |
| 1272 (35) 91.8 (27) 5.5 (20) 1.5 (4) 9.4 (84) 11.3 (20) 14.9 (33) 20.8 (4) 35.7 (31) 1.8 (4) 14.0 (7) 1.2 (16) 34.3 (1) 17.3 (3) 21.1 (12) 16.0 (18) 67.9 (4) 178.6 (14) 140.0 (1) 4.5 (23) 1.6 (3) 22.7 (5) 15.6 (4) 27.6 (1) 19.9 (6) 49.1 (16) 206.2 (8) 102.8 (20) 9.5 (7) 1.3 (7) 18.1 (16) 12.2 (13) 18.5 (19) 16.8 (29) 17.6 (12) 19.9 (6) 49.1 (16) 142.3 (33) 85.0 (34) 2.2 (39) 10.3 (33) 12.1 (31) 8.5 (31) 16.8 (29) 17.6 (12) 17.6 (12) 17.6 (12) 17.6 (12) 17.6 (13) 18.5 (13) 19.9 (6) 17.6 (12) 17.6 (12) 17.6 (13) 19.9 (16) 17.6 (12) 17.6 (13) 19.9 (14) 17.6 (15) | Croatia# | 212.0 (6) | 98.7 (24) | 11.4 (4) | 1.0 (29) | 22.5 (6) | 11.5 (18) | 18.5 (20) | - | 65.1 (6) | 8.9 (20) | 2.9 (29) | 4.9 (9) | 20.9 (14) | 8.5 (19) | 5.7 (12) | 3.1 (25) |
| \$\text{publics}\$ 229.3 (3) 124.7 (3) \ 7.0 (13) \ 12.7 (5) \ 34.3 (1) \ 173.6 (1) \ 193.6 (4) \ 276.6 (1) \ 199.6 (6) \ 49.1 (16) \ 200.2 (8) \ 102.8 (20) \ 9.5 (7) \ 1.3 (7) \ 18.1 (16) \ 12.2 (13) \ 18.5 (19) \ 12.8 (12) \ 12.8 (13) \ 18.5 (19) \ 12.8 (21) \ 18.2 (12) \ 84.8 (35) \ 11.3 (5) \ 13.6 (14) \ 20.8 (9) \ 14.0 (7) \ 20.8 (29) \ 14.0 (7) \ 20.7 (21) \ 18.5 (19) \ 15.6 (19) \ 15.8 (19) \ 1 | Cuba‡ | 127.2 (35) | 91.8 (27) | 5.5 (20) | 1.5 (4) | 9.4 (34) | 11.3 (20) | 14.9 (33) | 20.8 (4) | 35.7 (31) | 12.6 (12) | 5.3 (15) | 8.3 (1) | 6.4 (41) | 3.2 (38) | 4.6 (28) | 3.3 (17) |
| \$ 178.6(14) 140.0(1) 4.5(23) 1.6(3) 22.7(5) 15.6(4) 27.6(1) 19.9(6) 49.1(16) 206.2(8) 102.8(20) 9.5(7) 1.3(7) 18.1(16) 12.2(13) 18.5(19) 12.8(27) 66.4(5) 142.3(33) 85.0(34) 2.2(39) 1.0(33) 12.1(31) 8.5(31) 16.8(25) 17.6(12) 41.2(25) 188.2(12) 84.8(35) 11.3(5) 1.3(9) 16.6(22) 9.6(29) 19.6(16) 15.8(21) 46.5(19) 169.5(17) 103.3(17) 65.1(5) 12.1(4) 20.8(9) 14.0(7) 21.7(8) 16.6(16) 45.4(20) 145.7(31) 782.4(1) 1.9(44) 0.6(44) 8.0(35) 6.2(38) 16.2(27) 9.3(39) 49.8(15) 272.2(1) 138.4(2) 20.0(1) 2.4(1) 34.3(2) 18.7(2) 23.7(6) 18.7(11) 85.6(1) 17.16(16) 121.0(5) 4.4(24) 13.8(9) 12.8(18) 13.8(9) 25.1(4) 12.0(30) 27.1(35) 12.1(35) | Czech Republic§ | | 124.7 (3) | 7.0 (13) | 1.2 (16) | 34.3 (1) | 17.3 (3) | 21.1 (12) | 16.0 (18) | 67.9 (4) | 11.4 (14) | 5.0 (17) | 5.2 (8) | 15.5 (23) | 7.3 (22) | 7.0 (2) | 4.2 (6) |
| 2062 (8) 102.8 (20) 9.5 (7) 1.3 (7) 18.1 (16) 12.2 (13) 18.5 (19) 12.8 (27) 66.4 (5) 142.3 (33) 85.0 (34) 2.2 (39) 1.0 (33) 12.1 (31) 85.6 (31) 16.8 (25) 17.6 (12) 41.2 (25) 188.2 (12) 84.8 (35) 11.3 (5) 13 (9) 16.6 (22) 9.6 (29) 19.6 (16) 15.8 (21) 46.5 (19) 169.5 (17) 103.3 (17) 65.1 (15) 12.1 (4) 20.8 (9) 14.0 (7) 21.7 (8) 16.6 (16) 45.4 (20) 145.7 (31) 78.2 (41) 1.9 (44) 0.6 (44) 8.0 (35) 6.2 (38) 16.2 (27) 9.3 (39) 49.8 (15) 27.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 17.1 (16) 121.0 (5) 4.4 (24) 1.3 (8) 22.5 (7) 13.3 (9) 25.1 (4) 12.0 (30) 27.1 (35) 12.7 (| Denmark§ | | 140.0 (1) | 4.5 (23) | 1.6 (3) | 22.7 (5) | 15.6 (4) | 27.6 (1) | | 49.1 (16) | 28.0 (1) | 3.8 (21) | 3.5 (24) | 6.6 (38) | 3.1 (40) | 6.0 (10) | 3.9 (7) |
| 142.3 (33) 85.0 (34) 2.2 (39) 1.0 (33) 12.1 (31) 85.5 (31) 16.8 (25) 17.6 (12) 41.2 (25) 188.2 (12) 84.8 (35) 11.3 (5) 1.3 (9) 16.6 (22) 96.6 (29) 19.6 (16) 15.8 (21) 46.5 (19) 169.5 (17) 103.3 (17) 65.5 (15) 1.2 (14) 20.8 (9) 14.0 (7) 21.7 (8) 16.6 (16) 45.4 (20) 145.7 (31) 782.4 (41) 1.9 (44) 0.6 (44) 8.0 (35) 6.2 (36) 16.2 (27) 9.3 (39) 49.8 (15) 277.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 17.1 (16) 121.0 (5) 4.4 (24) 1.3 (8) 22.5 (7) 13.3 (9) 25.1 (4) 12.0 (30) 27.1 (35) 12.0 (31) 27.1 (35) 14.5 (22) 12.0 (31) 27.1 (35) 14.5 (32) 12.0 (31) 27.1 (35) 14.5 (32) 12.0 (31) 27.1 (35) 14.5 (32) 12.0 (31) 27.1 (35) | Estonia§ | 206.2 (8) | 102.8 (20) | 9.5 (7) | 1.3 (7) | 18.1 (16) | 12.2 (13) | 18.5 (19) | 12.8 (27) | 66.4 (5) | 7.0 (28) | 5.7 (13) | 4.6 (14) | 26.0 (8) | 12.0 (6) | 6.8 (3) | 4.9 (1) |
| 1882 (12) 84.8 (35) 11.3 (5) 1.3 (9) 16.6 (22) 9.6 (29) 19.6 (16) 15.8 (21) 46.5 (19) 169.5 (17) 103.3 (17) 6.5 (15) 1.2 (14) 20.8 (9) 14.0 (7) 21.7 (8) 16.6 (16) 45.4 (20) 145.7 (31) 78.2 (41) 1.9 (44) 0.6 (44) 8.0 (35) 6.2 (38) 16.2 (27) 9.3 (39) 49.8 (15) 272.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 17.1 (16) 121.0 (5) 4.4 (24) 13 (8) 22.5 (7) 13.3 (9) 26.1 (2) 18.8 (10) 44.5 (22) 127.1 (36) 104.5 (15) 1.5 (45) 0.7 (40) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 17.0 (12) (20) | Finland‡ | 142.3 (33) | 85.0 (34) | 2.2 (39) | 1.0 (33) | 12.1 (31) | 8.5 (31) | 16.8 (25) | 17.6 (12) | 41.2 (25) | 6.9 (29) | 1.0 (43) | 2.4 (34) | 10.2 (30) | 4.7 (32) | 4.7 (25) | 3.2 (21) |
| 169.5 (17) 103.3 (17) 6.5 (15) 1.2 (14) 20.8 (9) 14.0 (7) 21.7 (8) 16.6 (16) 45.4 (20) 145.7 (31) 78.2 (41) 1.9 (44) 0.6 (44) 8.0 (35) 6.2 (38) 16.2 (27) 9.3 (38) 49.8 (15) 272.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 17.1 (16) 121.0 (5) 4.4 (24) 1.3 (8) 22.5 (7) 13.3 (9) 26.1 (2) 18.8 (10) 44.5 (22) 127.1 (36) 104.5 (15) 15.6 (4) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 12.0 (20) 27.1 (35) | Francet | 188.2 (12) | 84.8 (35) | 11.3 (5) | 1.3 (9) | 16.6 (22) | 9.6 (29) | 19.6 (16) | 15.8 (21) | 46.5 (19) | 6.1 (34) | 1.6 (42) | 3.4 (26) | 7.2 (37) | 2.8 (42) | 5.6 (14) | 3.3 (16) |
| * 272.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 171.6 (16) 121.0 (5) 4.4 (24) 1.3 (8) 22.5 (7) 133 (9) 26.1 (2) 18.8 (10) 445 (22) 127.1 (36) 104.5 (15) 15.6 (4) 17.9 (18) 138 (8) 25.1 (4) 12.0 (30) 27.1 (35) 12.0 (4) 13.0 (5) 12.0 (10) 12 | Germany† | 169.5 (17) | 103.3 (17) | 6.5 (15) | 1.2 (14) | 20.8 (9) | 14.0 (7) | 21.7 (8) | 16.6 (16) | 45.4 (20) | 9.4 (17) | 2.8 (30) | 2.8 (30) | 12.0 (26) | 6.3 (27) | 5.5 (16) | 3.5 (14) |
| * 272.2 (1) 138.4 (2) 20.0 (1) 2.4 (1) 34.3 (2) 18.7 (2) 23.7 (6) 18.7 (11) 85.6 (1) 171.6 (16) 121.0 (5) 4.4 (24) 1.3 (8) 22.5 (7) 133 (9) 26.1 (2) 18.8 (10) 44.5 (2) 127.1 (36) 104.5 (15) 1.5 (45) 0.7 (40) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) 17.0 (10) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) 27.1 (35) | Greece§ | 145.7 (31) | 78.2 (41) | 1.9 (44) | 0.6 (44) | 8.0 (35) | 6.2 (38) | 16.2 (27) | 9.3 (33) | 49.8 (15) | 7.1 (25) | 0.9 (44) | 2.3 (35) | 8.2 (36) | 4.3 (34) | (6) 0.9 | 3.6 (12) |
| 171.6(16) 121.0(5) 4.4(24) 1.3(8) 22.5(7) 13.3(9) 26.1(2) 18.8(10) 122.1(36) 104.5(15) 1.5(45) 0.7(40) 17.9(18) 13.8(8) 25.1(4) 12.0(30) | Hungary** | | 138.4 (2) | 20.0 (1) | 2.4 (1) | 34.3 (2) | 18.7 (2) | 23.7 (6) | 18.7 (11) | 85.6 (1) | 20.3 (5) | 6.5 (10) | 4.8 (13) | 18.8 (18) | 8.7 (18) | 7.4 (1) | 4.4 (4) |
| 127.1 (36) 104.5 (15) 1.5 (45) 0.7 (40) 17.9 (18) 13.8 (8) 25.1 (4) 12.0 (30) | Ireland‡ | 171.6 (16) | 121.0 (5) | 4.4 (24) | 1.3 (8) | 22.5 (7) | 13.3 (9) | 26.1 (2) | 18.8 (10) | 44.5 (22) | 18.6 (7) | 3.1 (26) | 2.3 (36) | 10.7 (28) | 5.1 (30) | 4.6 (27) | 3.0 (34) |
| CONTENT CONTENT CONTENT AND A CONTENT | Israel§ | | 104.5 (15) | 1.5 (45) | 0.7 (40) | 17.9 (18) | 13.8 (8) | 25.1 (4) | | 27.1 (35) | 8.7 (21) | 1.7 (41) | 3.0 (27) | 8.6 (34) | 5.1 (31) | 6.1 (8) | 4.2 (5) |
| (24) 10.1 (47) 10.1 (47) 10.1 (41) 11.1 (41) 11.1 (42) 11.1 (43) 11.1 (43) | Japan## | 155.2 (25) | 75.7 (42) | 3.1 (31) | 0.8 (37) | 17.1 (21) | 9.9 (28) | 7.7 (43) | 5.1 (42) | 31.7 (33) | 8.5 (22) | 1.9 (36) | 2.0 (42) | 30.2 (4) | 12.3 (5) | 4.1 (36) | 2.5 (41) |

| Kazakstan§ | 207.6 (7) | 102.9 (19) | 7.7 (11) | 1.9 (2) | 12.6 (30) | 8.6 (30) | 13.2 (34) | 5.7 (39) | 62.3 (10) | 8.5 (23) | 6.2 (12) | 4.6 (15) | 33.1 (2) | 13.9 (2) | 3.3 (43) | 2.6 (40) |
|--------------------|------------|------------|----------|----------|-----------|------------|-----------|-----------|-----------|-----------|----------|----------|-----------|-----------|----------|----------|
| Kyrgyzstan§ | 123.5 (37) | 72.4 (43) | 3.6 (28) | 1.0 (31) | (68) 6.9 | 4.5 (41) | 10.6 (37) | 4.3 (43) | 25.5 (36) | 4.3 (40) | 6.2 (11) | 3.5 (25) | 29.1 (5) | 10.7 (10) | 2.5 (45) | 2.0 (45) |
| -atvia‡ | 224.0 (4) | 107.6 (9) | 7.9 (10) | 1.2 (21) | 18.3 (12) | (11.8 (15) | 17.3 (24) | 11.5 (31) | 63.6 (8) | 5.9 (37) | 4.2 (19) | 5.4 (7) | 26.8 (7) | 11.8 (7) | 5.8 (11) | 3.8 (8) |
| -ithuania§ | 203.7 (10) | 101.0 (21) | 8.5 (9) | 1.0 (30) | 18.2 (13) | 11.7 (16) | 18.7 (18) | 15.2 (22) | 62.5 (9) | 5.3 (38) | 7.4 (7) | 4.8 (12) | 25.9 (9) | 10.2 (11) | 6.6 (4) | 4.5 (3) |
| Macedonia§ | 137.4 (34) | 82.3 (38) | 2.6 (35) | 0.7 (42) | 10.8 (33) | 7.1 (34) | 16.1 (30) | 6.2 (38) | 39.6 (28) | 6.7 (31) | 3.1 (25) | 5.5 (6) | 22.0 (11) | 9.7 (13) | 4.4 (31) | 2.4 (42) |
| Mauritius§ | 80.3 (45) | 65.2 (44) | 4.3 (25) | 1.2 (20) | 6.0 (42) | 3.8 (44) | 9.0 (41) | 7.7 (36) | 16.7 (42) | 4.0 (41) | 5.5 (14) | 8.3 (2) | 10.8 (27) | 5.7 (28) | 3.5 (41) | 2.1 (44) |
| Mexico‡ | 85.0 (44) | 78.9 (40) | 1.9 (43) | 0.7 (41) | 3.6 (45) | 3.3 (45) | 9.3 (39) | 12.8 (26) | 16.2 (43) | 6.0 (35) | 14.0 (1) | 2.1 (41) | 9.7 (31) | 7.1 (23) | 3.9 (39) | 3.1 (28) |
| Vetherlands‡ | 182.3 (13) | 108.0 (8) | 2.8 (33) | 1.0 (32) | 17.7 (19) | 12.7 (11) | 26.0 (3) | 19.4 (8) | 62.0 (11) | 13.6 (9) | 1.7 (40) | 2.2 (37) | 10.3 (29) | 4.2 (35) | 5.7 (13) | 3.1 (29) |
| New Zealand¶ | 167.2 (18) | 121.2 (4) | 2.7 (34) | 1.2 (13) | 26.4 (3) | 19.1 (1) | 22.9 (7) | 19.8 (7) | 39.6 (27) | 18.8 (6) | 3.4 (23) | 2.1 (40) | 6.0 (43) | 3.2 (39) | 6.1 (7) | 4.5 (2) |
| Vorway‡ | 146.6 (30) | 103.3 (18) | 3.1 (30) | 1.0 (34) | 20.0 (11) | 14.7 (5) | 19.4 (17) | 23.2 (2) | 31.7 (32) | 13.3 (11) | 3.1 (24) | 2.9 (29) | 9.1 (33) | 4.6 (33) | 4.3 (32) | 2.8 (37) |
| Poland§ | 204.9 (9) | 107.6 (11) | 6.3 (17) | 1.1 (25) | 16.4 (23) | 11.0 (22) | 16.1 (29) | 11.1 (32) | 71.3 (2) | 11.1 (15) | 7.3 (8) | 3.8 (22) | 18.9 (17) | 6.8 (25) | 5.6 (15) | 3.5 (15) |
| Portugal§ | 155.0 (26) | 84.3 (36) | 6.4 (16) | 0.8 (38) | 18.1 (15) | 10.4 (24) | 17.6 (22) | 17.2 (13) | 29.2 (34) | 4.6 (39) | 2.6 (32) | 4.1 (18) | 21.8 (12) | 10.0 (12) | 5.0 (22) | 3.2 (19) |
| Rep. of Moldova‡ | 162.4 (20) | 88.9 (30) | 11.7 (3) | 1.3 (10) | 16.2 (25) | 11.1 (21) | 18.2 (21) | 5.7 (40) | 43.0 (24) | (96) 0.9 | (6) 9.9 | 4.4 (17) | 20.7 (15) | 9.2 (16) | 5.2 (20) | 3.1 (26) |
| Romania§ | 150.7 (27) | 88.5 (31) | 7.1 (12) | 1.2 (18) | 11.3 (32) | 7.9 (33) | 15.7 (32) | 8.3 (35) | 44.8 (21) | 7.2 (24) | 10.5 (4) | 4.1 (19) | 17.6 (21) | 6.8 (26) | 4.5 (29) | 3.0 (30) |
| Russian Fed.‡ | 237.1 (2) | 107.6 (10) | 9.1 (8) | 1.1 (26) | 18.2 (14) | 12.6 (12) | 16.1 (28) | 7.2 (37) | 70.5 (3) | 7.0 (27) | 5.0 (16) | 4.9 (11) | 36.9 (1) | 15.3 (1) | 5.1 (21) | 3.5 (13) |
| Slovakia‡ | 218.1 (5) | 103.5 (16) | 16.8 (2) | 1.2 (15) | 14.6 (28) | 6.8 (35) | ì | 12.2 (29) | 64.2 (7) | 7.1 (26) | i i | 1.0 (44) | 5 | 3 | 3.4 (42) | 2.2 (43) |
| Slovenia§ | 200.9 (11) | 107.4 (12) | 10.7 (6) | 1.0 (28) | 23.9 (4) | 14.0 (6) | 21.2 (11) | 14.7 (23) | 61.1 (12) | 9.1 (19) | 4.0 (20) | 4.9 (10) | 19.7 (16) | 8.3 (20) | 5.4 (18) | 3.2 (20) |
| Spain‡ | 173.2 (15) | 79.8 (39) | 7.0 (14) | 0.9 (36) | 16.4 (24) | 10.0 (27) | 17.5 (23) | 13.9 (24) | 48.7 (17) | 3.9 (42) | 1.8 (38) | 3.0 (28) | 12.7 (25) | 5.6 (29) | 5.2 (19) | 3.2 (23) |
| Sweden§ | 123.3 (38) | 94.4 (26) | 2.2 (40) | 0.9 (35) | 13.8 (29) | 10.2 (26) | 16.8 (26) | 21.4 (3) | 22.3 (37) | 12.0 (13) | 1.8 (37) | 2.5 (32) | 6.6 (39) | 3.5 (37) | 4.5 (30) | 3.2 (24) |
| Trinidad & Tobago¶ | 107.3 (41) | 99.4 (23) | 4.6 (22) | 1.4 (6) | 7.8 (37) | 8.3 (32) | 21.5 (9) | 35.5 (1) | 11.2 (45) | 3.7 (44) | 8.2 (6) | 7.1 (4) | 8.4 (35) | 7.7 (21) | 4.2 (35) | 2.9 (36) |
| Turkmenistan¶ | 120.8 (39) | 86.0 (33) | 5.8 (19) | 1.5 (5) | 6.2 (40) | 4.4 (42) | 9.5 (38) | 1.4 (44) | 17.3 (41) | 3.7 (43) | 3.7 (22) | 3.8 (21) | 18.3 (20) | 11.0 (9) | 3.1 (44) | 2.9 (35) |
| United Kingdom† | 164.2 (19) | 116.5 (6) | 2.9 (32) | 1.1 (22) | 18.0 (17) | 11.6 (17) | 24.5 (5) | 16.6 (15) | 46.6 (18) | 20.5 (4) | 3.0 (28) | 2.1 (39) | 9.5 (32) | 3.9 (36) | 4.7 (26) | 3.0 (32) |
| Venezuela¶ | 104.3 (42) | 90.0 (28) | 2.5 (37) | 1.2 (11) | 5.9 (43) | 6.2 (39) | 11.8 (36) | 20.3 (5) | 19.4 (40) | 9.3 (18) | 10.8 (2) | 7.4 (3) | 16.8 (22) | 9.7 (14) | 4.1 (37) | 3.1 (27) |

Frates are age-adjusted to the World Health Organization World standard population.
† 1994-1997; ‡1994-1995; § 1994-1996; ¶ 1994 only; ** 1996-1997; # 1995-1996; ## 1995-1997.
& Oral cancer mortality rate includes nasopharymx only.

~ Data not available Source: Mortality Database 1994-1997, World Health Organization, 1999.

VOL. 50 NO. 1 JANUARY/FEBRUARY 2000